ClinicalThought
View More
 |
   |
 |
Deciding which patients with chronic hepatitis B should be treated is not as simple as determining if their ALT and DNA levels fall above guideline thresholds. Here’s my take.
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Preventing mother-to-child transmission of HBV infection is critical to ensure the long-term health of the newborn. Here’s how we can prevent infection in infants born to mothers with HBV infection.
Maria Buti, MD
Released: April 29, 2020
The early detection of HCC in patients with chronic HBV infection means the difference between curable vs terminal disease. Here is how I ensure I do not miss HCC in my patients.
Steven L. Flamm, MD
Released: June 16, 2020
What are the pros and cons of discontinuing oral therapy with nucleos(t)ide analogues in patients with chronic HBV infection? Here’s my take.
Pietro Lampertico, MD, PhD
Released: July 10, 2020
How do you distinguish between patients who are true inactive carriers and those with immune active HBeAg-negative chronic hepatitis B? Here’s my take.
Anna Christina L. dela Cruz, MD
Released: August 18, 2020
In this interactive virtual module, expert faculty discuss how they would manage complex patients with HBV infection, emphasizing European guidelines and perspectives.
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Maria Buti, MD
Pietro Lampertico, MD, PhD
Physicians:
maximum of 1.25 AMA PRA Category 1 Credits™
Released: June 1, 2020
Expired:
No longer available for credit
Review European guideline recommendations informing HBV management strategies for complex cases and learn how expert faculty would approach each case
Maria Buti, MD
Pietro Lampertico, MD, PhD
Released: June 1, 2020
In this interactive virtual module, expert faculty discuss how they weigh various patient factors to aid in management decisions for patients with HBV infection; topics include treatment candidacy, individualizing treatment, patient monitoring, and approaches to immune-tolerant HBV infection.
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Steven L. Flamm, MD
Physicians:
maximum of 1.25 AMA PRA Category 1 Credits™
Released: July 7, 2020
Expired:
No longer available for credit
Review guideline recommendations and key data on evaluating patient and disease characteristics to inform treatment candidacy and the optimal treatment approach; topics include treatment options, patient monitoring, and approaches to immune-tolerant HBV infection.
Steven L. Flamm, MD
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Released: July 7, 2020
In this interactive virtual module, expert faculty discuss how they would manage complex patients with HBV infection based on individual patient factors and current guidelines; topics include fibrosis assessment, pregnancy, and using qHBsAg to assess inactive carrier status.
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Joseph Ahn, MD, MS, MBA
Anna Christina L. dela Cruz, MD
Physicians:
maximum of 1.0 AMA PRA Category 1 Credit™
Released: July 20, 2020
Expired:
No longer available for credit
Review guideline recommendations informing HBV management strategies for complex cases and learn how expert faculty would approach each case; topics include fibrosis assessment, pregnancy, and using qHBsAg to assess inactive carrier status.
Joseph Ahn, MD, MS, MBA
Anna Christina L. dela Cruz, MD
Released: July 21, 2020
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.